ArticleEJHaem2025
Epidemiology, Survival, and Second Primary Malignancies in T-Cell Large Granular Lymphocytic Leukemia.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Introduction: Large granular lymphocytic leukemia (LGL) is a rare lymphoproliferative disorder, with limited literature available about the epidemiology, survival, and development of secondary primary malignancies (SPMs) in T-LGL. Methods: The Surveillance, Epidemiology, and End Results (SEER) 17 registry was used to identify all cases of T-LGL diagnosed between 2000 and 2019, and patients with primary T-LGL were analyzed. Results: Patients with primary T-LGL were found to have a higher incidence of SPMs compared to the general population, with increased risk for hematological malignancies seen within the first 10 years and solid tumors seen after 10 years of T-LGL diagnosis. Conclusion: Patients with primary T-LGL were found to have a higher incidence of SPMs. Further research is needed to better understand the reason for this increased risk. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.